BOSTON, Aug. 5, 2015 /PRNewswire/ — Karuna Pharmaceuticals, Inc. (“Karuna”), a PureTech (PureTech Health plc PRTC.L) company developing a novel product candidate for the treatment of schizophrenia, announced today that it has received a Translation Fund Award from the Wellcome Trust comprising an unsecured convertible loan to Karuna of up to $3.84 million. The funding, along with other capital, will be applied to further develop Karuna’s lead program KarXT, a potentially innovative therapy for the treatment of schizophrenia. read more
Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis
SYDNEY and SOUTHAMPTON, England, Aug. 5, 2015 /PRNewswire/ –Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology company Synairgen plc (LSE: SNG) today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2 enzyme is being targeted because it is known to promote scar tissue which hardens and irreparably damages the lungs of IPF patients. It is hoped that the inhibition of LOXL2 will slow the build-up of scar tissue and improve survival rates that are worse than for many cancers. read more
World Economic Forum Selects HealthTap as Technology Pioneer HealthTap honored with prestigious award for its groundbreaking end-to-end virtual health hub
PALO ALTO, Calif.–(BUSINESS WIRE)–HealthTap today announced that it has been selected as a 2016 Technology Pioneer by the World Economic Forum for its significant global potential to make virtual healthcare accessible to everyone. This prestigious distinction honors the world’s most innovative technology companies developing and implementing proven technologies that hold true promise to change the world. To be selected as a Technology Pioneer, a company must demonstrate the ability to design and deliver transformative, cutting-edge innovations. Prior WEF Technology Pioneers include Google, Twitter, Airbnb, Dropbox, and Nest Labs. read more
Transparency Life Sciences Announces Start Of Ulcerative Colitis Clinical Trial Assessing Feasibility Of Decentralized Patient Data Collection
NEW YORK, Aug. 5, 2015 /PRNewswire/ — Transparency Life Sciences, LLC (TLS), a clinical-stage drug development company based on open innovation, today announced that the first patient has been enrolled in an innovative ulcerative colitis clinical trial designed to assess the feasibility of replacing most conventional patient site visits with data collected using a combination of decentralized methods, including digital measurements, telemonitoring, remote video visits with clinical trial staff and blood collections by visiting nurses. In addition, the study is the first to allow key clinical endpoint assessments to be made by the subjects’ own gastroenterologists, rather than via designated sub-investigators affiliated with the trial. read more